Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?

BACKGROUND: A significant amount of common variable immunodeficiency (CVID) patients manifest with autoimmunity. Particularly, autoimmune thrombocytopenia (AITP) is commonly seen. Intravenous immunoglobulins (IVIG) are an established treatment option for both, CVID and AITP. Nonetheless, due to fewe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Scheuerlein, Philipp, Pietsch, Larissa, Camacho-Ordonez, Nadezhda, Reiser, Veronika, Patel, Smita, Burns, Siobhan O., Warnatz, Klaus, Grimbacher, Bodo
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6060403/
https://ncbi.nlm.nih.gov/pubmed/30072997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01656
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados